Ikervis

Ciclosporin, the active ingredient in Ikervis, is a calcineurin inhibitor presented as a 0.1% w/v ophthalmic emulsion for ocular use. It is indicated for the treatment of dry eye disease and keratoconjunctivitis sicca, providing anti‑inflammatory activity on the ocular surface in adult patients.

GNH USA supplies Ikervis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets.

Ikervis (ciclosporin ophthalmic emulsion) is used to manage ocular surface inflammation associated with dry eye disease and related conditions. - Dry eye disease: reduces ocular surface inflammation and improves tear film stability. - Keratoconjunctivitis sicca: decreases inflammatory cytokine production, relieving discomfort and visual disturbance. - Inflammatory ocular surface disease: mitigates signs of inflammation, supporting corneal health and patient comfort.

Ikervis may cause ocular and systemic adverse reactions; reported events vary in frequency and severity.

Common Side Effects: - Burning sensation: transient discomfort upon instillation. - Stinging or itching: mild irritation that usually resolves. - Redness of the eye: conjunctival hyperemia. - Blurred vision: temporary visual disturbance after dosing. - Eye discharge: mild tearing or mucus. - Foreign body sensation: feeling of grit in the eye.

Serious or Rare Side Effects: - Corneal ulceration: ulcer formation requiring immediate medical attention. - Persistent intraocular inflammation: ongoing inflammation that may threaten vision. - Vision loss: rare but severe decrease in visual acuity. - Allergic reaction: swelling, rash, or systemic hypersensitivity.

When prescribing Ikervis, clinicians should observe the following precautions to ensure safe use. - Hypersensitivity: avoid use in patients with known allergy to ciclosporin or any excipient. - Ocular infection: do not initiate treatment if active bacterial, viral or fungal eye infection is present. - Intraocular pressure: monitor pressure periodically, especially in glaucoma patients. - Contact lens wear: advise patients to remove lenses before instillation and wait before reinserting. - Persistent irritation: discontinue if severe burning or redness persists beyond a few days. - Store at room temperature: keep in the original container, protect from light and moisture.

Ikervis can interact with other ophthalmic or systemic agents; awareness of these interactions helps minimize risk.

Major Interactions (Avoid): - Systemic ciclosporin: concurrent use may increase systemic immunosuppression. - Live vaccines: immunosuppression can reduce vaccine efficacy and increase infection risk. - Other ocular immunosuppressants: combined therapy may heighten risk of ocular infection.

Moderate Interactions (Monitor Closely): - Topical non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase ocular irritation. - Anticholinergic eye drops: could affect tear production and drug distribution. - Contact lens wear: lenses may retain drug, altering exposure and comfort.